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We report the development and validation of a new sensitive,
accurate and precise HPLC method with ultraviolet detection for
the determination of indinavir sulfate (IND) in human plasma and
its application to a bioequivalence study of a new generic
formulation. The extraction of IND from plasma samples was
achieved by using liquid-liquid extraction with a mean recovery
of 73.9%. The lower limit of quantification was 0.05 µg/mL.
Bioequivalence between the products was determined by
calculating 90% confidence intervals (CI) for the ratio of Cmax,
AUC0-t and AUC0-inf values for the test and reference products, within
the 0.80-1.25 interval proposed by ANVISA and FDA. Therefore
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The use of generic drugs can improve health pattern
and life quality through a larger number of people
consuming cheaper drugs. For antiretroviral agents in par-
ticular, it means an extraordinary progress for the human
rights and health equity, especially in developing countries.
Generic drugs are available to the Brazilian
population since 1999 when the Act 9.787 was established,
following the conceptual model adopted by European
countries, the United States, Canada and recommended by
the World Health Organization (WHO). The generic drugs
policy improved control of drug prices practiced by
Pharmaceutical Industries in Brazil, allowed effective
market competition, as well as the selection of reference
products and priorities for generics production. In addition,
quality, safety and efficacy requisites were revised
including the more stringent monitoring of Good
Manufacturing Practices (GMP) in the pharmaceutical
industry and regular control of drug quality (Storpirtis et al,
2004).
Indinavir sulfate (CAS 157810-81-6), chemically
designated as (alpha-R, gamma-S, 2S)-alpha-benzyl-2-
(tert-butylcarbamoyl) - gamma - hydroxyl - N - [(1S, 2R)-
2-hydroxy-1- indanyl] -4-(3-pyr idylmethyl) -1-
piperazinevaleramide sulfate (1:1) (salt), is a selective,
competitive, reversible inhibitor of HIV protease, an
enzyme that plays an essential role in HIV replication and
in the formation of infectious virus. Indinavir (Figure 1) is
a structural analog of HIV Phe-Pro protease cleavage site
(Jayewardene et al., 1998; Zhong, Yeh, 1999; Turner et al.,
2003; Justesen et al., 2003).
The drug structure inhibits the function of HIV
protease, blocking virus maturation and causing the
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formation of immature, noninfectious virions. Indinavir is
active in both acutely and chronically infected cells while
nucleoside reverse transcriptase inhibitors (NRTIs) do not
affect chronically infected cells (Woolf et al., 1997;
Jayewardene et al., 1998; Foisy, Sommadossi, 1999; Lin,
1999; Rose et al., 2000; Turner et al., 2003; Justesen et al.,
2003). While indinavir does not affect early stages of the
HIV replication cycle, it does interfere with the production
of infectious HIV, limiting further infectious spread of the
virus. In vitro studies indicate that the antiretroviral effects
of HIV protease inhibitors and some NRTIs or Non-
nucleoside reverse transcriptase inhibitors (NNRTIs) may
be additive or synergistic (Burger et al., 1997; Aymard et
al., 2000; Yamada et al., 2001; Justesen et al., 2003;
Hurwitz, Schinazi, 2002;Chi et al., 2002; Rentsch, 2003).
It is rapidly absorbed in the fasted state, with peak plasma
concentration of 0.8 ± 0.3 hours (Lin, 1997; Yeh et al.,
1999; Raffani, Haas, 2003).
Indinavir has been detected in low concentrations in
cerebrospinal fluid of adults and children receiving the drug
(Lin, 1997; Zhong Yeh, 1999; Hass et al., 2000; Svensson
et al., 2000; Megard et al., 2002). Protein binding of
indinavir is approximately 60% over a range of 0.05 to
10 μg/mL (Raffani, Haas, 2003; Schon et al., 2003).
Indinavir is mainly metabolized by the liver (Woolf et al.,
1997; Rentsch, 2003; Lin, 1997; Langmann et al., 1999;
Justesen et al., 2003; Raffani, Haas, 2003). Plasma half-
life averages 1.8 hours in adults and 1.1 hours in children
(Lin, 1997). Indinavir is excreted primarily in the faeces
both as unaltered drug and as metabolites. Following a 400
mg oral dose, 83% were recovered in faeces (19.1% as
unchanged drug) and 19% were recovered in urine (9.4%
as unchanged drug) (Raffani, Haas, 2003).
Several high-performance liquid-chromatographic
(HPLC) assays, using UV detection, have been reported for
the determination of indinavir in serum/plasma (Heeswijk
et al, 1998; Hugen et al., 1999; Svensson et al., 2000;
Dailly et al., 2001; Sarasa-Nacenta et al., 2001; Villani et
al., 2001; Marzolini et al., 2002; Turner et al., 2003) either
alone (Rose et al., 2000; Justsen et al., 2003), or together
with its metabolites (Langman et al., 1999; Hurwitz,
Schinazi, 2002). However, the need for a time and cost-
saving method meeting the current GLP guidelines for the
analysis of indinavir in human plasma, stimulated us to
investigate the usefulness of a new simple and fast method
with sensitivity and selectivity appropriated to perform the
quantification of indinavir in human plasma.
This paper describes the development and validation
of an accurate, precise, specific, sensitive and inexpensive
HPLC method for indinavir quantification in human plas-
ma using verapamil as internal standard (I.S.), and its
application to a bioequivalence study between two




Acetonitrile (ACN) was purchased from EM Science
(Gibbstown, NJ, USA); Methyl tert-butyl ether (MTBE)
was purchased from Mallinckrodt Baker (Phillipsburg, NJ,
USA). Methanol, sodium hydroxide and phosphoric acid,
ammonium chloride and di-sodium hydrogen phosphate
were purchased from Merck (Rio de Janeiro, RJ, Brazil).
Acetonitrile and methanol were used as HPLC grade
solvents and all other reagents as analytical grade.
Indinavir was obtained from Hetero drugs
(Hyderabad, India), verapamil (internal standard) was
purchased from Sigma Chemicals (St Louis, MO, USA).
Ultra pure water was prepared using Milli-Q (Millipore,
Molsheim, France). Blank human blood was collected from
healthy, drug-free volunteers. Plasma was obtained by
centrifugation of blood treated with an anticoagulant. Plas-
ma was prepared and stored at approximately -20 ºC.
Instruments and chromatographic conditions
The HPLC analysis were performed on a Shimadzu
chromatographic system (Kyoto, Japan) composed by a
LC-10AD VP pump, a SIL-10A VP auto-sampler, a SPD-
10A VP UV detector and a SCL 10 A-VP controller unit.
FIGURE 1 - Chemical structures of indinavir (A) and
verapamil (B) used as an internal standard.
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The analytical column used was a Phenomenex Luna® C8
10 mm, 250 x 4.6 mm, Securityguard® guard column
(Torrance, USA). Acquired data was processed with
CLASS-VP (v.6.2) software running under Windows 98 on
a Pentium PC. The mobile phase was a mixture of di-
sodium hydrogen phosphate (0.01 M) + ammonium
chloride (0.4%) with pH adjusted to 4.5 (solvent A) and
ACN (solvent B), 68:32, v/v, pumped at a flow rate of 1.8
mL/min through the column. Peaks were monitored at 210
nm at 30 °C. Quantification of indinavir was done by
measuring the response (area) of indinavir in relation to the
response of ritonavir (internal standard).
Standard solutions
Stock solutions of indinavir (1 mg/mL) were
prepared in methanol-water (1:1, v/v). Working standard
solutions were prepared from the stock solution by
sequential dilution with ACN - water (1:1, v/v) to yield fi-
nal concentrations of 1, 10 and 100 µg/mL.
Stock solutions of the I.S. (1 mg/mL) were prepared in
methanol. Working internal standard solutions were prepared
from the stock solution by sequential dilution with methanol
to yield final concentrations of 1, 80 and 100 μg/mL. Stock
and working standard solutions were protected from light
and stored at – 20 °C until used. Calibration standards were
obtained by adding known amounts of indinavir to drug-free
plasma to achieve concentrations of 0.01, 0.02, 0.05, 0.1,
0.2, 0.5, 1, 2, 5, 10 and 15 μg/mL. Three quality controls of
low (0.15 μg/mL), middle (4.5 μg/mL) and high (9.0 μg/mL)
concentrations were prepared by adding known amounts of
indinavir to drug-free plasma. Plasma solutions were
protected from light and stored at –70 °C until used.
Extraction procedure for indinavir and verapamil
(I.S.) from plasma
Indinavir and I.S. were extracted from human plas-
ma samples by liquid-liquid extraction. Calibration
standards, validation control samples and volunteers’ plas-
ma samples were prepared by aliquoting 250 µL of plasma.
The plasma sample was transferred to a 2 mL
polypropylene screw capped tube and 20 µL of internal
standard solution (80 µg/mL) was added. The contents of
the tubes were mixed by vortexed and 1 mL of the
extraction solvent (MTBE) was added. After vortexing
(5 min), tubes were centrifuged (5000 rpm for 5 min). The
tubes were then placed in dry ice-acetone bath, the lower
aqueous layers were frozen, and the organic phase was
transferred to clean 10 mL glass tubes. The solvent was
evaporated under a stream of nitrogen at 40 °C. The
resulting residue was reconstituted in 150 µL of the mobi-
le phase: 100 µL aliquot of the supernatant was transferred
to the injection vials and 50 µL were injected into the
chromatographic system. The quality controls samples
were analyzed in duplicate for each batch. All samples from
a single volunteer were analyzed in the same day in order
to avoid inter-assay variation.
Method validation
The specificity of the method was determined by
comparing chromatograms obtained from plasma
containing indinavir and I.S. with those obtained from
blank samples. Possible interference from other drugs was
investigated by examining their peak separation from
indinavir using the same HPLC conditions.
The lower limit of quantification (LLOQ) was the
smallest analytical concentration which could be measured
with precision and accuracy.
In order to perform the analysis of indinavir in human
plasma, the analytical recovery of indinavir was determined
at concentrations of 0.15, 4.5, and 9.0 µg/mL (n=5). Drug-
free plasma was spiked with known amounts of the drug to
achieve the concentration previously specified. These
samples were processed by the analytical method described
above and peak areas were compared with that obtained by
direct injection of the drugs in the mobile phase.
To assess linearity, study was carried out in the range
of 0.01 to 15 μg/mL. The linearity test was done by spiking
drug-free plasma with known amounts of the drug to achieve
the concentrations of 0.01, 0.02, 0.05, 0.1, 0.2, 0.5, 1, 2, 5,
10 and 15 μg/mL.
In order to perform the analysis of indinavir in human
plasma, the precision and accuracy or data were obtained
by analyzing aliquots of three-spiked plasma samples at
low (0.15 μg/mL) middle (4.5 μg/mL) and high (9.0 μg/
mL) concentration levels of indinavir. Intra-day
reproducibility was determined by analyzing 5 aliquots of
spiked human plasma and inter-day reproducibility was
determined over 3 consecutive days.
Standard solutions were stored at room temperature
and at 4 °C. These samples were used to investigate the
stability of indinavir over a period of 1 week. Drug-free
plasma was spiked with known amounts of the drug to
achieve concentrations of 0.15, 4.5 and 9.0 µg/mL (n=5).
They were stored at -70 °C. These samples were used to
investigate the long-term stability of indinavir over a period
of 9 months. In addition, short-term stability studies of
plasma samples spiked with indinavir were performed for
6 hours period at room temperature storage and for three
freeze-thaw cycles.
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Bioequivalence study
The analytical method was applied to evaluate the
bioequivalence of two capsule formulations of indinavir in
healthy volunteers: Crixivan® capsules 400 mg (standard
reference formulation) and indinavir capsules 400 mg (test
formulation).
Twenty-six adult volunteers, with an average age of 23
years, average height of 1.75 m and average body weigh of
74.22 kg and with 15% of the ideal body mass, were selected
for the study after assessment of their health status by clinical
evaluation (physical examination, ECG) and the following
laboratory tests: blood glucose, urea, creatinine, aspartate
aminotransferase (AST), alanine aminotransferase (ALT),
alkaline phosphatase, γ-gluthamil transferase (γ-GT), total
bilirubin, albumin and total protein, triglyceride, total
cholesterol, hemoglobin, hematocrit, total and differential
white cell counts, and routine urinalysis. All volunteers were
negative for human immunodeficiency virus (HIV), hepatitis
C virus (HCV), and hepatitis B virus (HBV), except for
serological scar. The volunteers were free from significant
cardiac, hepatic, renal, pulmonary, gastrointestinal,
neurological and hematological disease as determined within
four weeks before the beginning of the study. All volunteers
gave written consent and the Ethical Committee of Univer-
sidade Federal de Pernambuco approved the clinical
protocol.
The study was an open, single dose, randomized,
two-period crossover trial with a 1-week washout period.
The volunteers were hospitalized, had a regular meal and
received a 400 mg capsule of the formulation. After
administration of the coated tablet, the volunteers were
asked to drink 300 mL of water. Blood samples for plasma
drug assay were taken from a forearm vein before indinavir
administration and at 0.25, 0.5, 0.75, 1.0, 1.25, 1.5, 2.0,
2.5, 3.0, 4.0, 6.0, 8.0 and 12 hours after it. Heparinized
venous blood samples (8  mL) were collected by means of
an indwelling venous canula. The blood samples were
centrifuged at 2000 g for ten minutes and the plasma
removed and stored at -70 °C until assayed. The volunteers
received a standard meal five hours after dosing. Six hours
after dose administration a standard lunch was available.
Liquids were allowed ad libitum after lunch, but xanthine-
containing foods and beverages, such as tea, coffee and cola
were not permitted 48 h prior to each dosing and until the
collection of the last blood sample.
Pharmacokinetic and statistical analysis
Bioequivalence between the two formulations was
assessed by calculating individual test/reference ratios for
the peak of concentration (Cmax), area under curve (AUC)
of plasma concentration until the last concentration
observed (AUC0-t), and the area under curve between the
first sample (pre-dosage) and infinite (AUC0-inf). The Cmax
and the time taken to achieve this concentration (Tmax) were
obtained directly from the curves. The areas under the
indinavir plasma concentration vs. time curves from 0 to
the last detectable concentration (AUC0-t) were calculated
by applying the linear trapezoid rule. Extrapolation of these
areas to infinity (AUC 0-inf) was done by adding the value
Clast /ke to the calculated AUClast (where Clast = the last
detectable concentration, and ke = the first-order terminal
elimination rate constant which was estimated by linear
regression from the points describing the elimination phase
on a log-linear plot). The AUC and Cmax data for the two
formulations were analyzed by analysis of variance
(ANOVA) to establish whether the 90% confidence interval
(CI) of the ratios was within the 80–125% interval
indicating bioequivalence as proposed by the US Food and
Drug Administration. Parametric and non-parametric
analysis of indinavir transformed arithmetic means and
individual Tmax differences between test and reference
formulations were performed.
RESULTS
Validation of HPLC method
The alternative HPLC-UV method described,
validated and used here for drug quantification, provides
adequate sensitivity, specificity and high sample throughput
required for pharmacokinetic studies.
Figure 2 shows the described chromatographic
conditions, the retention times for indinavir and I.S. were
10.6 and 12.8 min, respectively, at a flow rate of 1.8 mL/
min. It also shows that no endogenous interfering peaks
appeared at the retention times of the compounds of
interest.
The average absolute recovery of indinavir in plasma
was 73.9%. The LLOQ for indinavir was 0.05 µg/mL. The
lower limit of quantification was 0.05 µg/mL, with relative
standard deviation lower than 10%. The calibration curve
was linear over the range 0.05 µg/mL to 15.0 µg/mL, with
a regression coefficient ≥ 0.99 and intercept not
significantly different from zero (Figure 3).
The obtained analytical precision and accuracy for
intra-day and inter-day assays of three quality controls
(0.15, 4.5 and 9.0 µg/mL) are presented in Table I. The
overall variability of the quality controls (0.15, 4.5 and 9.0
µg/mL; n=52) was 6.2, 2.7 and 5.1%, respectively; the
accuracy was 100.4, 99.9 and 99.9%, respectively. No
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significant degradation of indinavir was observed during
this period under storage conditions.
Organic extracts were stable at room temperature for
at least 48 hours. Plasma samples were stable for at least 270
days at -70 °C and also after three freeze-thawing cycles.
These results indicate that analyte is stable in human
plasma and makes it an acceptable method for bioequivalence
studies.
Bioequivalence evaluation
Safety was evaluated by monitoring adverse events
and vital signs and through physical examination, clinical
laboratory tests and electrocardiograms. Each volunteer
was questioned periodically throughout the study regarding
adverse effects.
Indinavir was well tolerated at the administered dose,
and no adverse effects were reported. Mean indinavir plas-
ma concentration–time profiles and average values of
pharmacokinetic parameters after test and reference
products administration obtained after 400 mg of indinavir
FIGURE 3 – Standard calibration curve for indinavir
quantification in human plasma by HPLC method with UV
detection.
FIGURE 2 - Typical chromatographic of (A) blank human plasma; (B) blank human plasma spiked with indinavir (0.05
μg/mL) and internal standard (verapamil, 16 μg/mL); (C) plasma from healthy volunteer after oral administration of 400
mg of indinavir, spiked with internal standard (verapamil 16 μg/mL).
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to 26 healthy human volunteers are shown in Figure 4 and
Table II, respectively. The power of statistical test was
> 80% for AUC0-t, AUC0-inf and Cmax
DISCUSSION
The HPLC method used here proved to be simple,
fast, reliable, selective, sensitive and economic enough to
be used in clinical pharmacokinetic studies of indinavir in
humans. A bioavailability study involving the standard
indinavir formulation was initially conducted to verify the
usefulness of the developed method. Once the methods were
successfully applied, a full bioequivalence study was
carried out.
Several high-performance liquid chromatography
(HPLC) methods have been reported for the determination
of indinavir levels in animal and human plasma. These
methods use gradient HPLC or HPLC with column
switching and liquid chromatography – mass spectrometry
(Jayewardene et al., 1998, 2001). These assay methods are
relatively time-consuming or they use expensive
instrumentation not readily accessible to many groups.
Furthermore these methods presented a small calibration
range. Therefore, our goal was to develop a relatively rapid
and costless assay that could be performed at any
laboratory with adequate HPLC instrumentation.
Jayewardene et al. (1998) described a simple and
reproducible method for monitoring indinavir levels in
human plasma, with ether extraction and direct UV detection.
The overall recovery of indinavir from human plasma during
extraction prior to analysis was 91.4%, in the range 0.25–
5.00 µg/ml, indicating good precision and accuracy.
However, the data reported suggest that the reproducibility
at low levels was not fully satisfactory and the run time was
about 30 min. The coefficient of variation of the peak height
ratio was 11% for 0.075 µg/mL (six replicates).
Foisy et al. (1999) described a rapid and sensitive
method consisting of solid-phase extraction and separation on
a reversed-phase C8 column using a simple binary mobile
phase of phosphate buffer - ACN (60:40, v/v) and HPLC
analysis with UV detection at 210 nm, with a LLOQ of 0.025
µg/mL. However, the use of solid phase extraction increases
the total cost of the analysis, especially when a large number
of samples were analyzed (Jayewardene et al., 1998).
These difficulties prompted us to develop a new simple
and fast method with sensitivity and selectivity appropriated
to perform the quantification of indinavir in human plasma,
meeting the GLP guidelines for bioavailability and
bioequivalence studies (FDA, 1993, 1998 a,b).
The HPLC method described here was accurate, pre-
cise, sensitive and capable of determining concentrations of
indinavir in small volumes of human plasma. The extraction
procedure described is simple and a commercially available
I.S. (verapamil) was used. However, different extraction
procedures were initially tested. Solid phase extraction with
C18 extraction cartridges were investigated. Although the
extraction using C18 cartridges proved to be reproducible
and the extraction efficiency was higher than 80%, manual
SPE is laborious and automated SPE systems are expensive
and not readily available. Furthermore the costs related to the
SPE cartridges are prohibitive to many laboratories.
Liquid phase extraction methods using low amounts
of different organic solvents were then tried, and clean
blank chromatograms were obtained. Liquid phase
extraction method using MTBE showed the best results,
yielding clean extracts with a run time of 15 min.
Mean plasma decay curves (Figure 4) and pharmaco-
kinetic parameters (Table II) obtained for the test product
were similar to those obtained for the reference product
(Crixivan®). The results of ANOVA revealed the absence
of period, group and product effects and the power of
TABLE II - Mean pharmacokinetics parameters obtained in
26 healthy volunteers after the administration of indinavir
400 mg test and standard formulations
Pharmacokinetics parameters (IC 90%) Indinavir
(TEST)  (STD)
AUC0-24 h (mg*h*mL
-1)Geometric Mean 5.24 4.94
AUC0-inf (mg*h*mL
-1)Geometric Mean 5.47 5.22
Cmax (mg*mL
-1)Geometric Mean 3.49 3.43
t1/2 (h)Geometric Mean 1.35 1.42
Tmax (h)Median 0.75 0.75
TABLE I - Analytical precision and accuracy of the HPLC
determination of indinavir from spiked plasma samples
(n=5) – Intra- and Inter-day variation
Nominal Concentration Precision Accuracy
concentration Obtained Mean (%) (%)
(µg/mL) (µg/mL) ± SD
Intra-day
0.15 0.16 ± 0.006 4.17 110.3
4.50 4.66 ± 0.29 6.27 103.5
9.00 9.69 ± 0.57 5.94 107.7
Inter-day
0.15 0.15 ± 0.01 8.28 100.9
4.50 4.44 ± 0,21 4.88 98.7
9.00 9.06 ± 0.66 7.3 100.7
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statistical test indicates that the sample size (n = 26) was
adequate. The 90% confidence intervals for AUC0-t (0.95 –
1.18 mg*h*mL-1), AUC0-inf (0.95-1.16 mg*h*mL
-1) and
Cmax (0.92- 1.12 mg*h*mL
-1) are within the 0.80–1.25
interval proposed by the ANVISA and FDA. It was
concluded that the test formulation (indinavir 400 mg
capsules) and the reference formulation (Crixivan® 400 mg
capsules) are bioequivalent.
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RESUMO
Determinação de indinavir em plasma humano e sua
aplicação em estudo farmacocinético
Foi desenvolvido e validado um novo método, sensível,
exato e preciso por Cromatografia a Líquido de Alta Efi-
ciência com detecção em UV para a determinação do sul-
fato de indinavir (IND) em plasma humano. O fármaco foi
extraído do plasma através de extração líquido-líquido
obtendo recuperação média de 73.9%, com limite inferi-
or de quantificação de 0.05 µg/mL. O método foi aplica-
do em estudo de farmacocinética para verificar a
bioequivalência entre um novo medicamento genérico e
seu produto de referência. A bioequivalência entre os pro-
dutos foi determinada calculando-se um intervalo de con-
fiança (IC) de 90% para a razão das médias do produto
teste e referência compreendidas entre o intervalo de 0.80-
1.25 proposto pela ANVISA e O FDA. Os produtos estu-
dados são bioequivalentes e, portanto, intercambiáveis.
UNITERMOS: Indinavir/estudo farmacocinético. Plas-
ma. Medicamentos genéricos/política.
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